StreetInsider.com News Articles

Form 8-K Quoin Pharmaceuticals For: Oct 20

Tue, 20 Oct 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20261020/27206194.html

Quoin Pharmaceuticals publishes peer-reviewed paper on QRX003 for rare skin disease

Tue, 20 Oct 2026 06:33:35 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the publication of a peer-reviewed manuscript on its investigational drug QRX003 for Netherton Syndrome in the journal Dermatology and Therapy. The paper was published online on Oct. 13, 2026, and is available as open access.

The paper introduces QRX003, a topical serine protease inhibitor lotion, and describes its mechanism of action in Netherton Syndrome, a rare genetic skin disease caused by mutations in the SPINK5 gene. It also presents a case report from Professor Alan Irvine, a consultant dermatologist at Children's Health Ireland and professor of dermatology at Trinity College Dublin.

The case report details 21

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Tue, 20 Oct 2026 06:30:00 -0400

– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published

– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient

– Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch)

– After 21 Months of Treatment with QRX003, Patient’s Skin Remains Fully Clear and Pruritus Free

– No Adverse Events have Been Reported for the Patient

– Full Recruitment in Ongoing Phase 2/3 Netherton Syndrome Study Expected to Complete by End of 2026, with Topline

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Tue, 20 Oct 2026 06:30:00 -0400

– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published

– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient

– Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch)

– After 21 Months of Treatment with QRX003, Patient’s Skin Remains Fully Clear and Pruritus Free

– No Adverse Events have Been Reported for the Patient

– Full Recruitment in Ongoing Phase 2/3 Netherton Syndrome Study Expected to Complete by End of 2026, with Topline

Canaccord Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 19 Oct 2026 05:31:12 -0400

Canaccord analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $18.00.
The analyst comments: “Rare derm remains an attractive place for a biotech given significant unmet need and limited competition. Quoin’s lead program, QRX003, combines 4% DPHP with Invisicare, a topical delivery technology licensed from Skinvisible, and is being developed first for Netherton syndrome (NS), a rare genetic skin disease with no approved therapy. Early clinical data are encouraging, including the recent interim results from the Ph2/3 CL-QRX003-004 study, where patients washed out of other therapies and 4 of 6 achieved

Canaccord Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 19 Oct 2026 05:31:12 -0400

Canaccord analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $18.00.
The analyst comments: “Rare derm remains an attractive place for a biotech given significant unmet need and limited competition. Quoin’s lead program, QRX003, combines 4% DPHP with Invisicare, a topical delivery technology licensed from Skinvisible, and is being developed first for Netherton syndrome (NS), a rare genetic skin disease with no approved therapy. Early clinical data are encouraging, including the recent interim results from the Ph2/3 CL-QRX003-004 study, where patients washed out of other therapies and 4 of 6 achieved

Form 8-K Quoin Pharmaceuticals For: Oct 14

Wed, 14 Oct 2026 06:35:00 -0400
si-local-file:///var/storage/secattach/20261014/27183363.html

EMA grants orphan drug status to Quoin's QRX003 for skin disorder

Wed, 14 Oct 2026 06:30:15 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate QRX003 for the treatment of Peeling Skin Syndrome.

The designation provides Quoin with incentive benefits including scientific advice on study protocols, fee reductions, and access to EU grants. If the EMA grants marketing authorization, QRX003 would receive 10 years of market exclusivity in Europe for Peeling Skin Syndrome.

According to the company, this marks the eighth regulatory milestone for QRX003 across two indications. The U.S. Food and Drug Administration has previously granted QRX003 Pediatric Rare Disease Designation and Fast Track

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Wed, 14 Oct 2026 06:30:00 -0400

– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end

– Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union

– Designation Represents Eighth Important Regulatory Milestone for QRX003

– QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration

– In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Wed, 14 Oct 2026 06:30:00 -0400

– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end

– Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union

– Designation Represents Eighth Important Regulatory Milestone for QRX003

– QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration

– In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe

BTIG Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 12 Oct 2026 06:05:48 -0400

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $14.00.
The analyst comments "Quoin Pharmaceuticals (QNRX) is a clinical-stage biopharmaceutical company developing QRX003, a topical broad-spectrum serine protease inhibitor lotion, for Netherton Syndrome (NS), a rare skin disease with no FDA-approved therapies and an estimated 1,600-3,000 diagnosed pts in the US today. We see QRX003's broad kallikrein inhibition as differentiated and its clinical responses and clean safety profile addressing the large unmet need in NS. Depending on whether a randomized withdrawal study is needed or if the ongoing QRX003-004 study

BTIG Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 12 Oct 2026 06:05:48 -0400

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $14.00.
The analyst comments "Quoin Pharmaceuticals (QNRX) is a clinical-stage biopharmaceutical company developing QRX003, a topical broad-spectrum serine protease inhibitor lotion, for Netherton Syndrome (NS), a rare skin disease with no FDA-approved therapies and an estimated 1,600-3,000 diagnosed pts in the US today. We see QRX003's broad kallikrein inhibition as differentiated and its clinical responses and clean safety profile addressing the large unmet need in NS. Depending on whether a randomized withdrawal study is needed or if the ongoing QRX003-004 study

Form SCHEDULE 13G/A Quoin Pharmaceuticals Filed by: Ikarian Capital, LLC

Wed, 07 Oct 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20261007/27161977.html

Quoin Pharmaceuticals' QRX003 paper accepted in dermatology journal

Tue, 06 Oct 2026 06:32:45 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that a manuscript on its investigational drug QRX003 has been accepted for publication in Dermatology and Therapy, a peer-reviewed journal.
The paper, titled "An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report," describes QRX003's mechanism of action as a topical serine protease inhibitor lotion for Netherton Syndrome. It includes a case report from Professor Alan Irvine, consultant dermatologist at Children's Health Ireland and professor of dermatology at Trinity College Dublin, documenting his experience treating a pediatric patient under Quoin's Compassionate Use Program.
According to the paper, the treated patient

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Tue, 06 Oct 2026 06:30:00 -0400

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Tue, 06 Oct 2026 06:30:00 -0400

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of

Form DEF 14A Quoin Pharmaceuticals For: Nov 12

Fri, 02 Oct 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20261002/27143060.html

Form EFFECT Quoin Pharmaceuticals

Mon, 28 Sep 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260928/27109648.html

Form 424B3 Quoin Pharmaceuticals

Fri, 25 Sep 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260925/27107988.html

Lake Street Starts Quoin Pharmaceuticals (QNRX) at Buy

Wed, 23 Sep 2026 08:14:13 -0400

Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Quoin Pharmaceuticals click here. For more ratings news on Quoin Pharmaceuticals click here.
Shares of Quoin Pharmaceuticals closed at $7.01 yesterday.

Form PRE 14A Quoin Pharmaceuticals For: Nov 12

Tue, 22 Sep 2026 16:59:00 -0400
si-local-file:///var/storage/secattach/20260922/27091681.html

Form 8-K Quoin Pharmaceuticals For: Sep 22

Tue, 22 Sep 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260922/27091259.html

FDA grants fast track status to Quoin drug for peeling skin syndrome

Tue, 22 Sep 2026 08:30:53 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational drug QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.

According to the company, this is the first Fast Track Designation granted for a Peeling Skin Syndrome therapy. It is also the second such designation for QRX003, which previously received Fast Track Designation for Netherton Syndrome in March 2026.

The designation follows the FDA's clearance in July 2026 of Quoin's Investigational New Drug application for QRX003 in Peeling Skin Syndrome, which the company

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Tue, 22 Sep 2026 08:30:00 -0400

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Tue, 22 Sep 2026 08:30:00 -0400

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has